RANCHO
CORDOVA, Calif., Sept. 6,
2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc.
(Nasdaq: THMO), a market leader in automated cell processing tools
and services in the cell and gene therapy field, today announced
that Chris Xu, Ph.D., Chief
Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET, during the H.C. Wainwright 25th
Annual Global Investment Conference, taking place September 11-13, 2023, in New York.
Dr. Xu will also host in-person and virtual one-on-one meetings
during the event. Institutional investors who are registered for
the conference can log into www.hcwevents.com to request a meeting
with the company. Those interested in meeting with Dr. Xu outside
of the conference should contact Michael
Miller at mmiller@rxir.com.
About ThermoGenesis Holdings, Inc.
ThermoGenesis
Holdings, Inc. develops, commercializes, and markets a range
of automated technologies for CAR-T and other
cell-based therapies. The Company currently markets a full suite of
solutions for automated clinical biobanking,
point-of-care applications, and automation for
immuno-oncology, including its semi-automated, functionally
closed CAR-TXpress™ platform, which streamlines the
manufacturing process for the emerging CAR-T immunotherapy
market. For more information about
ThermoGenesis, please visit:
www.thermogenesis.com.
Contact Information
Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com
Investor Relations Contact:
Paula Schwartz, Rx
Communications
917-322-2216
pschwartz@rxir.com
View original
content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-present-at-the-hc-wainwright-25th-annual-global-investment-conference-301918883.html
SOURCE ThermoGenesis Holdings, Inc.